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Abstract
Background: Acute bacterial sinusitis (ABS) is a common infection in clinical practice. Data on
time to bacteriologic eradication after antimicrobial therapy are lacking for most agents, but are
necessary in order to optimize therapy. This was a prospective, single-arm, open-label, multicenter
study to determine the time to bacteriologic eradication in ABS patients (maxillary sinusitis) treated
with moxifloxacin.
Methods: Adult patients with radiologically and clinically confirmed ABS received once-daily
moxifloxacin 400 mg for 10 days. Middle meatus secretion sampling was performed using nasal
endoscopy pre-therapy, and repeated on 3 consecutive days during treatment. Target enrollment
was 30 bacteriologically evaluable patients (pre-therapy culture positive for Streptococcus
pneumoniae, Haemophilus influenzae or Moraxella catarrhalis and evaluable cultures for at least Day
2 and Day 3 during therapy visits), including at least 10 each with S. pneumoniae or H. influenzae.
Results: Of 192 patients enrolled, 42 were bacteriologically evaluable, with 48 pathogens isolated.
Moxifloxacin was started on Day 1. Baseline bacteria were eradicated in 35/42 (83.3%) patients by
day 2, 42/42 (100%) patients by day 3, and 41/42 (97.6%) patients by day 4. In terms of individual
pathogens, 12/18 S. pneumoniae, 22/23 H. influenzae and 7/7 M. catarrhalis were eradicated by day
2 (total 41/48; 85.4%), and 18/18 S. pneumoniae and 23/23 H. influenzae were eradicated by day 3.
On Day 4, S. pneumoniae was isolated from a patient who had negative cultures on Days 2 and 3.
Thus, the Day 4 eradication rate was 47/48 (97.9%). Clinical success was achieved in 36/38 (94.7%)
patients at the test of cure visit.
Conclusion: In patients with ABS (maxillary sinusitis), moxifloxacin 400 mg once daily for 10 days
resulted in eradication of baseline bacteria in 83.3% of patients by Day 2, 100% by Day 3 and 97.6%
by Day 4.
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Background
The increasing prevalence of bacterial resistance in acute
bacterial sinusitis (ABS) is of concern [1]. In particular,
penicillin resistance, macrolide resistance and trimetho-
prim-sulfamethoxazole resistance in Streptococcus pneumo-
niae, and β-lactamase production in Haemophilus
influenzae and Moraxella catarrhalis, can present clinical
problems in regions where their prevalence is high [1].
Worldwide, penicillin resistance has been reported in
about 20–30% of clinical isolates of S. pneumoniae [2-5],
while approximately 15–40% of isolates of H. influenzae
produce β-lactamase conferring resistance to ampicillin
[3-5]. High rates of β-lactamase production (over 90%)
and associated resistance have also been reported in M.
catarrhalis [3,5].
In vitro surveillance data demonstrate excellent activity of
the fluoroquinolone moxifloxacin against ABS pathogens,
including strains resistant to other antimicrobial classes
[5-7]. In addition, moxifloxacin shows good penetration
into sinus tissue, achieving concentrations in maxillary
sinus mucosa that range from 5- to 30-fold higher than
the minimum inhibitory concentration required to
inhibit growth of 90% (MIC90) of S. pneumoniae isolates 2
to 36 hours after the last 400 mg dose in a 5-day course
[8].
Currently, in the United States moxifloxacin 400 mg once
daily for 10 days is approved for the treatment of ABS.
This reflects the traditional practice of giving antimicro-
bial therapy for ABS for 10–14 days. However, new anti-
microbials are increasingly being investigated at shorter
treatment durations. For example, in previous studies in
ABS, moxifloxacin 400 mg once daily for 7 days had excel-
lent clinical efficacy, with clinical and bacteriologic suc-
cess rates ranging from approximately 92% to 97% [9-11].
Also, moxifloxacin 400 mg once daily for 7 days was clin-
ically and bacteriologically superior to cefuroxime axetil
250 mg twice daily for 10 days [11]. In a large post-mar-
keting study of moxifloxacin in ABS (N = 2405), 96% of
patients had improved by Day 5 and the clinical success
rate by Day 10 was 97% [12]. Studies with other antibiot-
ics have confirmed that shorter courses of therapy (3–5
days) produce comparable clinical and bacteriological
outcomes to longer courses [13-16].
Bacteriologic eradication data provide the most accurate
indication of antimicrobial effect in ABS. However, these
data are rarely collected and then only at the start and end
of therapy. In order to optimize the dosing duration, data
on the dynamics of bacteriologic eradication are required,
but these data are generally lacking for most antimicrobial
agents.
The objective of this study was to determine the time to
bacteriologic eradication following moxifloxacin therapy
in patients with ABS and positive pre-therapy bacterial
cultures.
Methods
Study design
This was a prospective, single-arm, open-label, multi-
center study conducted in adult patients with radiologi-
cally and clinically confirmed ABS. Patients received once-
daily moxifloxacin 400 mg for 10 days; however, addi-
tional or alternative antimicrobial therapy was permitted
if the patient was a failure following treatment with moxi-
floxacin. All patients underwent middle meatus secretion
sampling by means of nasal endoscopy pre-therapy, and
the procedure was repeated on 3 consecutive days during
treatment (Days 2, 3 and 4). Topical nasal medications
were not permitted within 4 hours before endoscopy.
Preparation of the nasal fossa, endoscopic sampling and
transport of the sample to the local microbiology labora-
tory were performed according to local practices at each
center. Antimicrobial susceptibility testing was performed
at each center using standard broth microdilution meth-
ods [17]. The study was conducted in accordance with the
Declaration of Helsinki and the protocol approved by the
ethical review board of each participating center.
Patient population
Subjects were males or females aged ≥18 years who had a
clinical diagnosis of ABS with signs and symptoms present
for ≥7 days but <28 days. ABS signs or symptoms were
defined as follows: evidence of air-fluid levels and/or
opacification on radiographic paranasal sinus film
(Waters' view) or limited CT scan; purulent secretions
obtained pre-therapy via middle meatus secretion sam-
pling using nasal endoscopy; and the presence of at least
one major and one minor symptom. Major symptoms
were purulent anterior or posterior nasal discharge, and
unilateral moderate or severe facial pain or malar tender-
ness; minor symptoms were cough or frequent throat
clearing, frontal headache, halitosis, and fever (oral
≥38.0°C/100.4°F, tympanic ≥38.5°C/101.2°F). All
women of childbearing potential enrolled in the study
had to have a negative urine pregnancy test and practice
adequate contraceptive use. Written informed consent
was obtained prior to enrollment.
Patients were excluded from the study if they had a history
of chronic sinusitis or symptoms of allergic rhinitis, previ-
ous or concomitant antimicrobial treatment, serious/sys-
temic infection, immunological impairment or terminal
illness, use of topical nasal or systemic steroids (unless the
dose had been stable for >4 weeks), or known hypersensi-
tivity to study medication. Other exclusion criteria were
pregnancy or breast feeding, risk of possible drug interac-BMC Ear, Nose and Throat Disorders 2006, 6:8 http://www.biomedcentral.com/1472-6815/6/8
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tions, severe liver disease, renal impairment, uncorrected
hyperkalemia, QTc  prolongation, quinolone-associated
tendinopathy, previous inclusion in this study or investi-
gational drug use in the last 30 days.
Efficacy evaluation
The primary efficacy variable was the proportion of
patients with bacteriologic eradication of pre-therapy
pathogens from middle meatus secretions on Days 2, 3,
and 4 in bacteriologically evaluable patients, i.e. the per-
protocol population. Patients in the per-protocol popula-
tion had to meet the study inclusion criteria, receive study
drug on Days 1–4 (except in the case of clinical failure
where two doses were required); have a positive baseline
culture for at least one of the following: S. pneumoniae, H.
influenzae, or M. catarrhalis; have evaluable culture speci-
mens obtained on Day 2 and Day 3 of treatment; receive
no other antimicrobial therapy from 7 days prior to
enrollment through day 4 of study drug administration
unless assessed as a clinical or bacteriological failure; and
have no protocol violation that would affect treatment
efficacy or evaluation.
Clinical efficacy was evaluated at the test of cure visit (0–
3 days post-treatment [Days 10–13]). Clinical success was
defined as resolution or improvement in the signs and
symptoms of ABS such that no further antimicrobial ther-
apy was required; clinical failure was defined as lack of
improvement or worsening of ABS symptoms such that
further antimicrobial therapy was required. The subset of
patients deemed clinically evaluable, i.e. the clinical effi-
cacy population, had to meet the inclusion criteria for the
study and receive at least 80% of the prescribed study drug
doses (except in the case of clinical failure where two
doses were required), have a valid clinical evaluation
available at the test of cure visit and no protocol violation
that would affect treatment efficacy or evaluation. Again,
no other antimicrobial therapy could be administered
from 7 days prior to enrollment until through the test of
cure visit unless the patient was assessed as a clinical or
bacteriological failure.
Safety evaluation
Clinical adverse events and laboratory data among all
moxifloxacin-treated patients were recorded. Adverse
events were classified according to the MedDRA glossary.
Statistical analysis
The planned sample size of 200 patients was based on
obtaining 30 valid per-protocol patients, including at least
10 each with S. pneumoniae or H. influenzae. Assuming an
80% eradication rate on Day 3 of therapy, the associated
95% confidence interval (CI) would be 65%-95%; these
limits were considered to provide sufficient precision.
Two-sided confidence intervals were calculated by exact
methods using SAS® software.
Results
Patient population
Eight sites in Argentina enrolled 65 patients and 22 sites
in the United States enrolled 127 patients, giving a total of
192 enrolled patients. The majority of patients (184/192,
95.8%) completed the study as planned. Eight patients
discontinued prematurely: 3 patients did not comply with
the protocol, 2 withdrew due to adverse events and 2 due
to insufficient therapeutic effect, and 1 was lost to follow-
up.
Of the 192 patients enrolled, 42 were bacteriologically
evaluable (per-protocol population), with 48 pathogens
isolated. Of these, 7 sites in Argentina enrolled 24 patients
and 13 sites in the United States enrolled 18 patients.
Only 1 patient who had a positive bacterial culture at
baseline was excluded from the per-protocol population;
this was due to the duration of the current episode of
sinusitis being too short (6 days). All 42 patients in the
per-protocol evaluation were bacteriologically evaluable
at Days 2, 3 and 4.
All patients in the per protocol population had maxillary
sinusitis. As assessed by the investigator, one patient had
a mild infection, 32 patients had moderate infections, and
nine had severe infections. The baseline demographic and
clinical characteristics of these patients are shown in Table
1.
Table 2 presents the baseline ABS signs and symptoms in
the per-protocol population. With the exception of halito-
sis, most patients had moderate to severe signs and symp-
toms. The most common presenting symptoms were
purulent nasal discharge and facial pain. Fever was
present in only 1 patient.
Of the 48 causative organisms identified from pre-treat-
ment cultures on Day 1 in the per-protocol population,
there were 23 H. influenzae, 18 S. pneumoniae and 7 M.
catarrhalis isolates. Six patients had 2 organisms isolated;
in 5 patients these were H. influenzae and S. pneumoniae; 1
patient had H. influenzae and M. catarrhalis. No strains
were typed. Susceptibility to moxifloxacin was deter-
mined for 45 isolates (3 H. influenzae isolates were not
tested). The moxifloxacin MIC90 (with MIC range) was
0.06 mg/L (0.015–0.06 mg/L) for H. influenzae, 0.250 mg/
L (0.06–0.25 mg/L) for S. pneumoniae and 0.06 mg/L
(0.03–0.06 mg/L) for M. catarrhalis. For azithromycin sus-
ceptibility the corresponding figures were 4.0 mg/L (0.5–
8.0 mg/L) for H. influenzae and 8.0 mg/L (0.125–16.0 mg/
L) for S. pneumoniae. For clarithromycin susceptibility the
figures were 16.0 mg/L (2.0–32.0 mg/L) for H. influenzaeBMC Ear, Nose and Throat Disorders 2006, 6:8 http://www.biomedcentral.com/1472-6815/6/8
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and 8.0 mg/L (0.125–8.0 mg/L) for S. pneumoniae. For
penicillin, the MIC90 against S. pneumoniae was 4.0 mg/L
(0.008–8 mg/L). All of the 7 M. catarrhalis strains and 7 of
the 20 H. influenzae strains tested (35%) were β-lacta-
mase-positive.
Primary efficacy outcome
Baseline bacteria were eradicated in 35/42 patients
(83.3%; 95% CI: 68.6, 93.0) by Day 2, 42/42 patients
(100%; 95% CI: 91.6, 100) by day 3, and 41/42 patients
(97.6%; 95% CI: 87.4, 99.9) by Day 4.
In terms of individual pathogens, 12/18 S. pneumoniae,
22/23 H. influenzae and 7/7 M. catarrhalis isolates were
eradicated by Day 2 (total 41/48; 85.4%) (Figure 1). Sus-
ceptibility data were available for 3 of the 6 S. pneumoniae
isolates and the 1 H. influenzae isolate that persisted; all 4
isolates remained susceptible to moxifloxacin, with MICs
identical to those recorded at baseline.
By Day 3, 18/18 S. pneumoniae isolates and 23/23 H. influ-
enzae isolates were eradicated (Figure 1). On Day 4, S.
pneumoniae was isolated from a patient who had negative
cultures on Days 2 and 3 (Figure 1). This patient was a
clinical success at the test of cure visit. The MIC for the
remaining S. pneumoniae isolate was 0.125 mg/L, which
was the same as that recorded at baseline.
Clinical outcome
Assessment of clinical outcome was outside the specified
time of the test of cure assessment for 4 patients in the per-
protocol group, and these were excluded from the clinical
efficacy analysis. In the per-protocol group 36/38 (94.7%;
95% CI: 82.3, 99.4) patients were clinical successes at the
test of cure visit. The remaining 2 patients were clinical
failures at the test of cure visit, but had shown clinical
improvement at Days 3 and 4 (during therapy). The base-
line pathogens for these 2 patients, (1 S. pneumoniae and
1 M. catarrhalis) were eradicated at Day 4.
A total of 162 patients were included in the clinical effi-
cacy population. The most common reason for exclusion
from this population was violation of the time schedule
(11 patients, i.e. test of cure visit outside Days 0–3 post-
treatment). At the test of cure visit 150/162 (92.6%; 95%
CI: 87.4, 96.1) patients were clinical successes. Of the 150
patients classes as clinical successes, 72 (48%) were totally
free of symptoms and 78 (52%) had improvements in
symptoms. The 12 patients classified as treatment failures
Bacterial eradication by pathogen Figure 1
Bacterial eradication by pathogen. Proportion of base-
line ABS pathogens eradicated from middle meatus secre-
tions at Days 2, 3, and 4 of moxifloxacin therapy.
Table 1: Baseline demographic and clinical characteristics (per-
protocol population)
Characteristic Per-protocol 
population (N = 42)
Sex, n male (%) 13 (31.0%)
Race, n (%)
white 34 (81.0%)
hispanic 6 (14.3%)
black 2 (4.8%)
Mean age at enrollment, years ± SD (range) 41.0 ± 15.2 (18.0–76.0)
Mean weight, kg ± SD (range) 74.8 ± 17.4 (41.0–
113.4)
Mean BMI ± SD (range) 27.0 ± 6.2 (18.0–46.9)
Location of infection, n (%)
left 13 (31.0)
right 13 (31.0)
bilateral 16 (38.1)
Severity of infection, n (%)
mild 1 (2.4)
moderate 32 (76.2)
severe 9 (21.4)
Median duration of infection, days (range) 11 (7–21)
SD, standard deviation
Table 2: Baseline severity of ABS signs and symptoms (per-
protocol population, N = 42)
Sign/symptom Patients (%) with severity of:
None Mild Moderate Severe
Purulent nasal drainage 1 (2.4) 2 (4.8) 17 (40.5) 22 (52.4)
Facial pain 3 (7.1) 4 (9.5) 19 (45.2) 16 (38.1)
Frontal headache 5 (11.9) 5 (11.9) 15 (35.7) 17 (40.5)
Throat clearing 6 (14.3) 10 (23.8) 20 (47.6) 6 (14.3)
Cough 9 (21.4) 9 (21.4) 12 (28.6) 12 (28.6)
Malar tenderness/pain 10 (23.8) 9 (21.4) 15 (35.7) 8 (19.0)
Halitosis 14 (33.3) 10 (23.8) 14 (33.3) 4 (9.5)BMC Ear, Nose and Throat Disorders 2006, 6:8 http://www.biomedcentral.com/1472-6815/6/8
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constituted a heterogeneous group, consisting of 7 males
and 5 females and ranging in age from 24–79 years
(mean: 46.2 years). Eight (67%) were white, 2 were black,
1 was Asian, and 1 Hispanic. The severity of infection at
baseline was mild in 1 patient, moderate in 6 patients,
and severe in 5 patients; 3 had bilateral sinusitis. All 12
patients were treated in the United States.
The safety (intent-to-treat) population included all
patients who received at least one dose of study drug (n =
187). In the safety population 168/187 (89.8%; 95% CI:
84.6, 93.8) were clinical successes at test of cure.
Safety
Because of missing information at one of the study sites
that would not permit confirmation of data, 5 of the 192
enrolled patients were not included in the safety popula-
tion. All 5 patients appear to have completed 10 days of
study drug, and only one patient had adverse events (mild
nausea and mild pyrosis). Of the 187 patients valid for the
safety analysis, 64 (34%) experienced at least one adverse
event and 29 (16%) reported at least 1 possibly or proba-
bly drug-related adverse event. The most common adverse
events considered to be possibly or probably drug-related
are listed in Table 3. Treatment was generally well toler-
ated. There were 2 withdrawals due to adverse events: one
due to an allergic reaction to study drug and one due to an
incarcerated inguinal hernia. There were no drug-related
serious adverse events although one patient developed an
inguinal hernia and an ileus that were both assessed as
serious and not related to study drug.
Discussion
This study showed high rates of bacteriologic eradication
of common ABS pathogens with moxifloxacin, 400 mg
once daily, in the first 2–4 days of therapy. In addition,
clinical success was achieved in a high proportion of
patients.
These results suggest that the duration of therapy could be
shortened without compromising clinical efficacy. How-
ever, the relationship between bacteriologic eradication
and clinical success in this study was not complete. One
patient with S. pneumoniae cultured at Day 4 was a clinical
success at Day 10–13, while 2 patients with bacteriologic
eradication at Day 4 were clinical failures at the test of cure
visit. Furthermore, this study was not designed to test
whether a shortened moxifloxacin course is effective in
the treatment of ABS.
In the case of the 1 patient who had a recurrence of S.
pneumoniae at Day 4, it is unknown whether this was a true
recurrence or a new infection. Also, failure to culture an
organism obtained from any microbiologic sample is a
good, but imperfect, indication of bacteriologic eradica-
tion. Direct endoscopic nasal cultures were obtained in
this study, rather than sinus puncture cultures. When
compared to sinus puncture cultures, endoscopic cultures
from the middle meatus have a sensitivity of 71.4% and a
specificity of 53.1% to detect any pathogen associated
with sinusitis [18]. However, for the detection of S. pneu-
moniae, H. influenzae and M. catarrhalis the sensitivity and
specificity improve to 85.7% and 90.6%, respectively, and
the positive predictive and negative predictive values are
80.0% and 93.5%, respectively [18,19]. This is consistent
with the results with a recent meta-analysis [19], which
found that for known pathogens the sensitivity and specif-
icity of endoscopically directed culture in acute bacterial
sinusitis were 80.9% and 90.5%, respectively, and the
positive predictive and negative predictive values were
82.6% and 89.4%, respectively. It could be that the nega-
tive cultures on Days 2 and 3 for the one patient with S.
pneumoniae culture at Day 4 represents either an inability
to detect low colony counts or sampling error.
Clinical success rates after 10 days of moxifloxacin ther-
apy were high for all patient populations analyzed;
94.7%, 92.6% and 89.8% for the per-protocol, clinical
efficacy and intent-to-treat populations, respectively.
These results are consistent with those predicted by the
Sinus and Allergy Health Partnership (SAHP) guidelines
using the Poole Therapeutic Outcome Model for fluoro-
quinolones (90–92% potential for clinical success) [1].
However, moxifloxacin has greater in vitro activity against
S. pneumoniae than other fluoroquinolones indicated for
use in ABS, such as levofloxacin and gatifloxacin [20,21].
Thus, the results of this study cannot be extrapolated to
other members of the class for this pathogen. To our
knowledge, only one other report has been made on time
to sinus sterilization with antibiotic therapy [22]. Of the
12 patients enrolled, only 10 were clinically evaluable and
the organisms isolated included S. pneumoniae (4 iso-
lates), S. aureus (2 isolates), coagulase-negative staphylo-
cocci (2 isolates), viridans group streptococci (1 isolate),
and Enterobacter aerogenes (1 isolate). For the S.pneumo-
niae, the median time to sinus sterilization was 50 hours
(range 24 to 74 hours); however, no firm conclusions can
be drawn from such a small sample number.
Table 3: Drug-related adverse events occurring in at least 2% of 
patients (safety population)
Adverse event, n (%) Safety population (N = 187)
Nausea 10 (5.3)
Dry mouth 4 (2.1)
Diarrhea 5 (2.7)
Irritability 4 (2.1)BMC Ear, Nose and Throat Disorders 2006, 6:8 http://www.biomedcentral.com/1472-6815/6/8
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The SAHP guidelines emphasize that pharmacodynamic
and pharmacokinetic properties are an important consid-
eration in the choice of antibiotic therapy for ABS [1].
Comparative data regarding the time to bacterial eradica-
tion would be useful to enable the development of
rational, optimized dosing schedules in ABS.
Conclusion
This study provided valuable data on the speed of eradica-
tion with moxifloxacin in patients with ABS and positive
pre-therapy bacterial cultures. Moxifloxacin therapy (400
mg once daily for 10 days) resulted in eradication of base-
line bacteria in 83.3% of patients by Day 2, 100% by Day
3 and 97.6% by Day 4. Early eradication of ABS pathogens
with moxifloxacin indicates the potential for optimiza-
tion of therapy duration with maintained high efficacy.
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